annb0t
Top 20
MELBOURNE, Australia, March 23, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) announces it has made significant progress in advancing the Company's glioblastoma multiforme (GBM) therapy candidate TLX101 into the next stage of clinical development.
TLX101 (4-L-[131I] iodo-phenylalanine, or 131I-IPA) is one of the Company's lead therapeutic clinical programs and has been granted orphan drug designation in the US and Europe. TLX101 targets L-type amino acid tran...
>>> Read more: Telix Advances Development of Glioblastoma Therapy Program
TLX101 (4-L-[131I] iodo-phenylalanine, or 131I-IPA) is one of the Company's lead therapeutic clinical programs and has been granted orphan drug designation in the US and Europe. TLX101 targets L-type amino acid tran...
>>> Read more: Telix Advances Development of Glioblastoma Therapy Program
